National Pension Service Purchases 42,450 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

National Pension Service increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 744,979 shares of the medical research company’s stock after purchasing an additional 42,450 shares during the period. National Pension Service owned approximately 0.19% of Thermo Fisher Scientific worth $387,560,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. AMF Tjanstepension AB acquired a new position in Thermo Fisher Scientific in the third quarter valued at $42,409,000. Howard Capital Management Group LLC increased its holdings in Thermo Fisher Scientific by 0.5% in the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after purchasing an additional 286 shares in the last quarter. Arkadios Wealth Advisors raised its holdings in shares of Thermo Fisher Scientific by 2.1% during the third quarter. Arkadios Wealth Advisors now owns 1,273 shares of the medical research company’s stock valued at $787,000 after purchasing an additional 26 shares during the period. Autumn Glory Partners LLC grew its stake in shares of Thermo Fisher Scientific by 107.1% in the 3rd quarter. Autumn Glory Partners LLC now owns 1,367 shares of the medical research company’s stock valued at $846,000 after buying an additional 707 shares during the period. Finally, Orrstown Financial Services Inc. increased its position in Thermo Fisher Scientific by 251.0% in the 3rd quarter. Orrstown Financial Services Inc. now owns 1,811 shares of the medical research company’s stock valued at $1,120,000 after buying an additional 1,295 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the sale, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,125 shares of company stock worth $11,231,699. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.8 %

NYSE:TMO opened at $539.86 on Wednesday. The business’s 50-day moving average is $548.80 and its two-hundred day moving average is $566.46. The firm has a market capitalization of $206.50 billion, a PE ratio of 32.66, a price-to-earnings-growth ratio of 2.99 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase program on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group upped their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Wells Fargo & Company raised their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 31st. Scotiabank increased their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. Finally, StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $656.86.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.